Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus

Bibliography

• Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-94
   PubMed Web of Science ®Google Scholar
• Taylor SR, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013;33:984-99
   PubMed Web of Science ®Google Scholar
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabetic Med 2010;27:136-42
   PubMed Web of Science ®Google Scholar
• Invokana (canagliflozin). Prescribing information. Janssen Ortho. LLC; Gurabo, PR 00778: 2013
   Google Scholar
• Farxiga (Dapagliflozin). Prescribing information. Bristol-Myers. Squibb Company; Princeton, NJ, USA: 2014
   Google Scholar
• Jardiance (Empagliflozin). Prescribing information. Boehringer. Ingelheim Pharmaceuticals, Inc; Ridgefield, CT, 06877 USA: 2014
   Google Scholar
• Fujimori Y, Katsuno K, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antibdiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327:268-76
   PubMed Web of Science ®Google Scholar
• Sykes AP, Kemp GL, Dobbins R, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2014;98-98:101
   Google Scholar
• Sykes AP, O’Connor-Semmes R, Dobbins R, et al. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2015;17:94-7
   PubMed Web of Science ®Google Scholar
• Sigafoos JF, Bowers GD, Castellino S, et al. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: Evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos 2012;40:2090-101
   PubMed Web of Science ®Google Scholar
• Hussey EK, Kapur A, O’Connor-Semmes R, et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013;14:25
   PubMed Web of Science ®Google Scholar
• Dobbins RL, O’Connor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012;14:15-22
   PubMed Web of Science ®Google Scholar
• Kapur A, O’Connor-Semmes R, Hussey EK, et al. First dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013;14:26
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and European Association for the Study of Diabetes. Diab Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Mikhail N. Place of sodium-glucose type 2 co-transporters inhibitors in treatment of type 2 diabetes. World J Diab 2014;5(6):854-9
   PubMedGoogle Scholar
• Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J 2015;108:1-6
   PubMed Web of Science ®Google Scholar
• Mudallar S, Armostrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diab Care 2012;35:2198-200
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZI, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in types 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diab Care 2015;37:1480-3
   Web of Science ®Google Scholar
• Bolinger J, Ljunggren O, Kulberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systemic review and meta-analysis. J Am Society Hypertension 2014;8:262-75
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
   PubMed Web of Science ®Google Scholar
• Zanoli L, Granata A, Lentini P, et al. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Scientific World J 2015. [Epub ahead of print]
   Google Scholar
• Scheen AJ. Phramacokinetics, pharmacodynamics and clinical use SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 2015. [ Epub ahead of print]
   Web of Science ®Google Scholar
• O’Connor-Semmes R, Walker S, Kapur A, et al. Pharmacokinetics and pharmacodynamics of the SGLT2 inhibitor remogliflozin etabonate in subjects with mild to moderate renal impairment. Drug Metab Dispos 2015;43:1077-83
   PubMedGoogle Scholar